Basel Medical Group Ltd announced changes to its board of directors. Outgoing directors Mr. Fung Keng Leong and Mr. Tan Boon Chye stepped down with immediate effect, though Mr. Tan will remain as chief commercial officer. The board appointed three new members: Mr. Yang Xinwen, Ms. Cao Juan, and Mr. Frederick Hong Shieh Ming (independent). The company states these appointments aim to broaden expertise in healthcare, business operations, capital markets, and investment advisory to support strategic growth. Basel Medical Group Ltd operates in the healthcare sector.

Basel Medical Group Ltd announced it has regained compliance with the Nasdaq minimum bid price requirement. This follows a period of non-compliance regarding the minimum share price threshold. The company operates in the healthcare industry, focusing on medical services and products.

Basel Medical Group Ltd filed unaudited consolidated financial statements and management's discussion and analysis for the six-month periods ended December 31, 2024, and December 31, 2025. The company operates in the healthcare industry, providing medical services.

Basel Medical Group Ltd announced a 1-for-12 reverse share split effective June 22, 2026, to comply with Nasdaq Marketplace Rule 5550(a)(2) regarding minimum bid price requirements. The consolidation of shares will reduce the number of issued and outstanding ordinary shares from 18,785,750 to approximately 1,565,480. Basel Medical Group Ltd is a medical clinic operator in Singapore.